NASDAQ:GWPH - GW Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$151.25 +0.24 (+0.16 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$151.25
Today's Range$149.02 - $152.76
52-Week Range$95.65 - $164.76
Volume324,519 shs
Average Volume401,915 shs
Market Capitalization$4.24 billion
P/E Ratio-21.76
Dividend YieldN/A
GW Pharmaceuticals logoGW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.01
Current Ratio11.32
Quick Ratio11.22


Trailing P/E Ratio-21.76
Forward P/E Ratio-15.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$11 million
Price / Sales381.84
Cash FlowN/A
Price / CashN/A
Book Value$13.92 per share
Price / Book10.87


EPS (Most Recent Fiscal Year)($6.95)
Net Income$-166,900,000.00
Net Margins-1,516.94%
Return on Equity-53.37%
Return on Assets-46.73%


Outstanding Shares27,770,000

GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals (NASDAQ:GWPH) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($3.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.22) by $0.90. The biopharmaceutical company earned $3.35 million during the quarter, compared to analysts' expectations of $2.04 million. GW Pharmaceuticals had a negative return on equity of 53.37% and a negative net margin of 1,516.94%. The firm's revenue was up 112.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.70) earnings per share. View GW Pharmaceuticals' Earnings History.

When is GW Pharmaceuticals' next earnings date?

GW Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for GW Pharmaceuticals.

What price target have analysts set for GWPH?

7 equities research analysts have issued 1-year target prices for GW Pharmaceuticals' shares. Their predictions range from $61.00 to $205.00. On average, they expect GW Pharmaceuticals' share price to reach $152.1429 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals.

What are Wall Street analysts saying about GW Pharmaceuticals stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (5/11/2018)
  • 2. Cantor Fitzgerald analysts commented, "Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19." (2/5/2018)

Who are some of GW Pharmaceuticals' key competitors?

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
  • Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)

Has GW Pharmaceuticals been receiving favorable news coverage?

News stories about GWPH stock have trended positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GW Pharmaceuticals earned a media sentiment score of 0.37 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are GW Pharmaceuticals' major shareholders?

GW Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Scopia Capital Management LP (9.78%), BlackRock Inc. (2.79%), Point72 Asset Management L.P. (1.31%), Rock Springs Capital Management LP (1.30%), Victory Capital Management Inc. (1.08%) and Millennium Management LLC (0.86%). View Institutional Ownership Trends for GW Pharmaceuticals.

Which major investors are selling GW Pharmaceuticals stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, OppenheimerFunds Inc., Franklin Resources Inc., Point72 Asset Management L.P., Hsbc Holdings PLC, AGF Investments Inc., C WorldWide Group Holding A S and Greenleaf Trust. View Insider Buying and Selling for GW Pharmaceuticals.

Which major investors are buying GW Pharmaceuticals stock?

GWPH stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Millennium Management LLC, Victory Capital Management Inc., UBS Group AG, JPMorgan Chase & Co., Rock Springs Capital Management LP, Alps Advisors Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for GW Pharmaceuticals.

How do I buy shares of GW Pharmaceuticals?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $151.25.

How big of a company is GW Pharmaceuticals?

GW Pharmaceuticals has a market capitalization of $4.24 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($6.95) on an earnings per share basis. GW Pharmaceuticals employs 583 workers across the globe.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]

MarketBeat Community Rating for GW Pharmaceuticals (GWPH)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  421 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  619
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.